In the first half of the year, the market of Chinese medicinal materials was still at a high level, and the prices of a large number of varieties continued to rise.

[Pharmaceutical Network Market Analysis] During the "14th Five-Year Plan" period, the basic position of Chinese medicinal materials in the development of traditional Chinese medicine and health service industry has become more prominent.
With the continuous strengthening of favorable policies, the Chinese medicinal materials industry will achieve great development
.

The industry predicts that in the first half of 2022, the overall market for Chinese herbal medicines may remain at a historically high level
.

It is reported that in March, the prices of many varieties of Chinese herbal medicines increased
.

According to relevant data, among the 1,445 varieties monitored by the market, there were 55 varieties of Chinese medicinal materials whose prices rose in March
.

Among them, cardamom is the product with higher growth in March, and Corydalis is the product with obvious rising trend in recent days
.

According to the supplier, the increase in the price of cardamom is mainly due to the temporary interruption of the arrival of goods from the port.
In addition, due to weather factors, the current supplier price of this product fluctuates from 115 yuan/kg to 130 yuan/kg
.

And Yanhusuo is a variety that is easily affected by the weather.
It takes man-hours to plant, and the market supply is not large.
Now it is in the midst of a shortage of new and old, so the market continues to rise
.

In addition to the above varieties, the varieties of Chinese herbal medicines whose prices have risen in March include clove, psoralea, raspberry, Digupi, purslane, Eclipta, and buffalo horn
.

 　　In addition, some media learned from the Chinese herbal medicine market on Wanshou Road in Xi'an that in recent months, 70% to 80% of the prices of Chinese herbal medicines have risen, including Poria, Astragalus, Chuanxiong, Coix seed and other Chinese herbal medicines with large sales volume
.

The price of tuckahoe has risen from about 15 yuan/kg in 2021 to 178 yuan per kilogram; the price of barley has risen from 12 or 3 yuan in 2021 to 20 yuan/kg now; astragalus, the price last year It was about 150/kg, and now it is 180 yuan/kg
.

 　　In addition, a market price monitoring report shows that throughout the year, the prices of many varieties have skyrocketed.

.

For example, the market price of Eclipta japonica has risen from around 3 yuan in March 2021 to 21 yuan today, and the increase has fluctuated by 600%
.

Rehmannia glutinosa, purslane, psyllium, rehmannia, etc.
rose by more than 200%
.

 　　Compared with 2021, the tribute chrysanthemum has increased by 50 yuan, and the current price is about 250 yuan/kg; the price of tangerine peel has increased by about 20% compared with 2021, and the current price is about 300 yuan/kg
.

The prices of some traditionally high-priced Chinese herbal medicines, such as saffron, bird's nest, American ginseng, velvet antler, and cordyceps, have risen in price
.

In addition, according to relevant media visits, the prices of animal medicinal materials have generally risen
.

As for the reasons for the price increase, the relevant person said that the state has issued regulations to strengthen the supervision of animal Chinese medicinal materials, and stricter management in terms of breeding, production, and epidemic prevention
.

 　　Regarding the rising prices of Chinese herbal medicines, analysts said that from the perspective of supply, the rise of Chinese herbal medicines in recent years is mainly affected by factors such as rising packaging materials and labor costs, the introduction of pharmacopoeia, and industry cycles
.

However, on the whole, there are few supporting factors for the continued increase in the prices of Chinese herbal medicines in 2022.
With the cycle change, it is expected that the prices of Chinese herbal medicines may begin to adjust and decline in the second quarter of 2022
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.